CSL CSL competitor Baxter Healthcare said its phase 3 trial did not meet its primary goals ..... efficacy in a sub-group of patients, which we expect Baxter to seek to confirm in further trials. The immunoglobulin
directors have deep experience in the international pharmaceuticals industry while the remaining directors have a range ..... of the three biggest industry players, along with Baxter International of the U.S. and Grifols of Spain. These three
Biogen Idec and Novo Nordisk are taking aim at Baxter 's Advate, and a less-frequent dosing schedule ..... convince physicians and patients to switch from Baxter 's established brand. Baxter temporarily shut down its Los Angeles plasma fractionation
respectively, could launch in early 2014. The $6 billion Factor VIII market looks particularly lucrative, but we note that Baxter BAX and Bayer have long-acting versions of their current blockbuster recombinant proteins that could reach the market in
respirator contract last year, combined with subdued infusion pump demand following recent market share gains during the Baxter BAX recall situation. The decline in dispensing revenue, however, fell short of our expectations as customers have delayed
decorated physician in the regenerative medicine space. Previously, he was the VP of New Therapeutic Development at Baxter ( BAX ) where he and his team developed a cell therapy product that reached unprecedented endpoints (now in Phase 3), not
Baxter International Inc ( BAX ) May 07, 2013 10:00 am ET ..... Meeting of the Shareholders of Baxter International . My name is Bob Parkinson ..... seekingalpha.com/article/1412051- baxter - international - inc -shareholder-analyst-call
Baxter International ( BAX ) slips 2.2% premarket after Phase III testing on its Alzheimer's drug immunoglobulin (IG) - always a long shot - failed to meet its co-primary endpoints. ( PR ) Post your comment!
NEW YORK, May 7 (Reuters) - Baxter International Inc : * Shares down 2.6 percent in premarket trade after alzeheimer's drug fail
May 7 (Reuters) - Baxter International Inc said a late-stage study of its experimental drug to treat Alzheimer's disease failed to reduce the decline of cognitive functions and preserve functional abilities.